In our studies, we used 1D11, a mouse monoclonal pan-TGF-β neutralizing antibody [35] and LY2109761, a chemical inhibitor of both TβR-I and TβR-II receptor kinases [40] to determine whether or not these two antagonists have non-overlapping spectra of anti-metastatic activity against breast cancer and whether anti-metastatic activity of TGF-β pathway inhibitors varies based on tissue tropism using a human basal cell-like breast cancer model. Here, TGFBR2 is linked to breast cancer.